# Artificial Intelligence In Bioinformatics Market

> Artificial Intelligence in Bioinformatics Market Research Report By Application (Drug Discovery & Development, Transcriptomics, Genomics Analysis, Proteomics Analysis, Metabolomics Analysis, DNA Sequencing, and Others), By Offering (Software, Services), By Deployment Mode (On-Premise, Cloud-Based), By End User (Pharmaceutical and Biotechnology Companies, Research Institutions, CDMO & CROs, Others) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East, and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 14.27%
- **2024:** $ 8.76 Billion
- **2025:** $ 10.02 Billion
- **2035:** $ 38.03 Billion
- **Key Players:** IBM (US), Illumina (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Siemens Healthineers (DE), Roche (CH), Agilent Technologies (US), Boehringer Ingelheim (DE), GSK (GB)

**Report ID:** MRFR/HCIT/20635-HCR · **Pages:** 144 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-bioinformatics-market-22235

---

## Market Summary

## **Artificial Intelligence in Bioinformatics Market Overview**

As per MRFR analysis, the Artificial Intelligence In Bioinformatics Market Size was estimated at 8.76 (USD Billion) in 2024. The Artificial Intelligence In Bioinformatics Market Industry is expected to grow from 10.02 (USD Billion) in 2025 to 33.28 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 14.27% during the forecast period (2025 - 2034).

### **Key Artificial Intelligence in Bioinformatics Market Trends Highlighted**

The Artificial Intelligence (AI) in the Bioinformatics market is poised for significant growth, driven by the rising adoption of AI technologies in healthcare and the increasing demand for personalized medicine. The market is expected to expand at a CAGR of 14.27%, reaching a market size of USD 25.5 billion by 2032. Some of the key market drivers in the AI in bioinformatics market include a higher rate of occurrence of chronic diseases, the increased necessity for early diagnosis and treatment, the fast development of AI algorithms, and computational power.

Equally important, government policies aimed at encouraging personalized medicine and health IT are stimulating market growth.

Opportunities for expansion are present in incorporating AI into different bioinformatics uses, including drug discovery, disease diagnosis, and customized therapy plans. In addition, AI's utilization in cloud computing and edge computing is giving birth to new prospects for its growth in the market. The most recent trends encompass AI-fueled bioinformatics platforms, machine learning employed in genetic variant interpretation, and deep learning applied to image-based diagnostics. With these advancements harnessed, the Artificial Intelligence Market will continue revolutionizing healthcare, leading to better personalized treatments and opening up new possibilities.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Artificial Intelligence in Bioinformatics Market Drivers**

Bioinformatics has grown so fast that AI technology is staggering forward, thus allowing researchers to rapidly and efficiently analyze huge amounts of biological data. In the next decade, technological innovations in AI are expected to significantly propel the growth of artificial intelligence in the bioinformatics market industry on a global scale. Some major technical advances include improved algorithms and machine learning methods. AI algorithms have become more intelligent, making them able to identify patterns more accurately and, hence, make predictions. This has led to the development of better AI-based tools for bioinformatics research.

There is much more biological data, such as genomic and proteomic information, leading to greater learning possibilities for AI algorithms. Therefore, building AI models will be highly accurate and reliable. Introduction of cloud-based platforms: Cloud-based platforms democratize access to artificial intelligence technologies for researchers who cannot afford their own infrastructure.

As a result, this will further boost the adoption rates of these technologies in bioinformatics. Continuous improvements in artificial intelligence technology are expected to define the trend of global growth of AI in the bioinformatics market industry over the next several years.

The field of personalized medicine, which is growing rapidly, aims at providing medical care that meets the unique needs of each patient. Personalized medicine, thanks to AI, has revolutionized how doctors can go through massive patient data to identify common features and predict what might happen to a given individual. In such an example, this data could be used to formulate better treatment plans that are more effective and individualized.

Further, the Application of artificial intelligence in drug discovery and development is advancing at pace. Consequently, AI-based tools may be used to scan millions of substances for promising drugs, detect new drug targets, and foresee the effectiveness and safety of newly designed medications. This will speed up the process of developing new drugs and make it more efficient.

## **Artificial Intelligence in Bioinformatics Market Segment Insights**

### **Artificial Intelligence in Bioinformatics Application Insights**

The Artificial Intelligence in Bioinformatics Market segmentation by Application is expected to reach a value of USD 10.2 billion by 2027, exhibiting a CAGR of 12.5% during the forecast period (2025-2034). [Drug Discovery](../../../reports/drug-discovery-services-market-5870) is a major application of AI in bioinformatics, with a market size of USD 2.5 billion in 2023 and an expected growth of USD 5.2 billion by 2027. AI can be used to analyze large datasets of biological data, including genomics, proteomics, and metabolomics data, to identify potential drug targets and develop new drugs more quickly and efficiently.

Biomarker Identification is another important application of AI in bioinformatics, with a market size of USD 1.8 billion in 2023 and an expected growth of USD 3.6 billion by 2027. AI can be used to identify biomarkers that can be used to diagnose diseases earlier and more accurately, as well as to develop personalized treatments. Genomics Analysis is a rapidly growing application of AI in bioinformatics, with a market size of USD 1.5 billion in 2023 and an expected growth of USD 2.9 billion by 2027.

AI can be used to analyze large datasets of genomic data to identify genetic variants that are associated with diseases and to develop new treatments for genetic diseases.

Proteomics Analysis is another important application of AI in bioinformatics, with a market size of USD 1.2 billion in 2023 and an expected growth of USD 2.3 billion by 2027. AI can be used to analyze large datasets of proteomics data to identify proteins that are associated with diseases and to develop new treatments for diseases that are caused by protein dysfunction. Metabolomics Analysis is a rapidly growing application of AI in bioinformatics, with a market size of USD 1.0 billion in 2023 and an expected growth of USD 2.0 billion by 2027.

AI can be used to analyze large datasets of metabolomics data to identify metabolites that are associated with diseases and to develop new treatments for diseases that are caused by metabolic disorders.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Artificial Intelligence in Bioinformatics Deployment Mode Insights**

On the basis of deployment mode, Artificial Intelligence in Bioinformatics Market can be categorized into cloud-based and on-premise. The bioinformatics field is witnessing widespread acceptance of cloud computing, a development that may have the cloud-based category controlling most of the market by 2023. All this has been possible thanks to cloud-based deployments, which are cost-effective, flexible, and scalable, among other benefits. Moreover, as they are web-based AI-driven bioinformatics tools and applications for planet-wide use, they do not call for any on-site infrastructure or maintenance.

However, it is anticipated that there will be a sluggish growth rate in the on-premise segment during the forecast period. On-premise deployments offer greater control and data security, particularly when supporting sensitive bioinformatics software.

Nevertheless, some firms might find it costly to set up and maintain infrastructure. In general, organizations will focus on deploying this technology through cloud-based methods since they want to enjoy its advantages, such as the low costs associated with procuring hardware and software, among others, in their bioinformatics requirements.

### **Artificial Intelligence in Bioinformatics End User Insights**

One of the key benefits of Artificial Intelligence in Bioinformatics Market is that it has been adopted by top-end users such as pharmaceutical and biotechnology companies, research institutes, CDMOs & CROs, etc., as a major tool. The Application of AI in drug discovery or development has made pharmaceutical and biotechnology companies dominate the market extensively. The global artificial intelligence bioinformatics market revenue was valued at USD 7.67 billion in 2023. This gives rise to an increased adoption of AI as a means of analysis and interpretation to drive the market.

AI is necessary for healthcare providers since it improves patient care in personalized medicine and early disease detection. To expand the market, governments invest in AI as part of public health initiatives. This industry's growth and innovation are driven by its adaptability to various end-users within bioinformatics, such as AI, based on different types of data sets across all types of medical information system users.

### **Artificial Intelligence in Bioinformatics Regional Insights**

North America is anticipated to be the market leader in the region, and it will take up a sizeable amount by 2023. This region’s domination is due to having major technology players, advanced healthcare infrastructure developments, and AI-based surrogates in the biotechnology industry. Europe will come second because of increased spending on AI research and development as well as other government incentives that also support their use in healthcare and life sciences industries.

The APAC region will experience outstanding growth during the forecast period compared to other regions, mainly due to an increase in personalized medicine demand, high healthcare costs, and government support for AI adoption into medical practice.

Nevertheless, South America and MEA are projected to have lower contributions towards the whole market, but they are forecasted to grow at considerable rates owing to advances made in AI-based drug discovery and precision medicines.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Artificial Intelligence in Bioinformatics Market Key Players and Competitive Insights**

Artificial intelligence in Bioinformatics market has been dominated by key players who are always striving to be ahead of their competitors through the creation of new products and solutions. The leading players in the Artificial intelligence bioinformatics market heavily invest in R&D so as to stay ahead of the current and adapt to the changing needs of customers. Strategic collaborations, partnerships, and acquisitions are among the characteristics that define the development landscape of Artificial Intelligence in Bioinformatics Market as firms seek to expand their portfolios, reach into new technologies, and explore new markets.

IBM is one of the major players in the Artificial Intelligence in Bioinformatics Market. Watson for Genomics represents a comprehensive portfolio of AI-enabled bioinformatics tools developed by IBM. It helps researchers process enormous genomics data sets. IBM has a strong presence across healthcare and life sciences industries, thus leveraging its domain expertise to drive AI adoption in bioinformatics. Another key player within this industry is Illumina, which is an AI-based high-throughput sequencing provider with various supportive genomic research tools they developed.

The main objective behind developing these AI-based approaches at Illumina includes identifying genetic variations, analyzing gene expression data, and coming up with personalized medications.

Thermo Fisher Scientific, QIAGEN, and Agilent Technologies are also other significant participants of Artificial Intelligence in Bioinformatics Market besides IBM and Illumina. These firms provide a wide array of AI-driven bioinformatic solutions that include analytics tools for drug discovery or precision medicine. There is stiff competition among these companies, so they constantly innovate to avoid being outdone.****

### **Key Companies in the Artificial Intelligence in Bioinformatics Market Include**

## **Artificial Intelligence in Bioinformatics Market Industry Developments**

To sum up, the adoption of AI in life sciences and healthcare will drive AI bioinformatics market growth significantly in the next few years. Increased database availability is among the major factors that are increasing market expansion. Moreover, the rise in cases of chronic ailments and individualized medication are also some of the drivers of this industry.

Of note, there have been recent changes that have led to the Introduction of new bioinformatics platforms based on AI. For instance, in 2023, IBM and Recursion Pharmaceuticals joined forces to use artificial intelligence (AI) in searching for drugs that can cure various rare diseases.

Major companies such as Microsoft, Google, Amazon, Oracle, and IBM are among the notable players here. These firms have made considerable investments towards developing AI-driven innovative bioinformatics solutions through research and development activities.

## **Artificial Intelligence in Bioinformatics Market Segmentation**

### **Artificial Intelligence in Bioinformatics Application Outlook**

## **Artificial Intelligence in Bioinformatics Deployment Mode Outlook**

### **Artificial Intelligence in Bioinformatics Data Offering Outlook**

### **Artificial Intelligence in Bioinformatics End User Outlook**

### **Artificial Intelligence in Bioinformatics Regional Outlook**

## Market Drivers

### Advancements in Drug Discovery

In the realm of drug discovery, the Artificial Intelligence in [Bioinformatics](https://www.marketresearchfuture.com/reports/bioinformatics-market-2265) Market is witnessing transformative advancements. AI-driven platforms are being utilized to identify potential drug candidates more efficiently, significantly reducing the time and cost associated with traditional methods. Reports suggest that AI can decrease the drug discovery timeline by up to 50%, which is a compelling incentive for pharmaceutical companies. The ability to analyze vast datasets and predict molecular interactions positions AI as a critical player in the bioinformatics landscape, fostering innovation and expediting the development of new therapeutics.

### Enhanced Collaboration Across Sectors

Collaboration between various sectors is a driving force in the Artificial Intelligence in Bioinformatics Market. Partnerships between academic institutions, research organizations, and biotechnology firms are fostering innovation and accelerating the development of AI-driven bioinformatics solutions. These collaborations often lead to the sharing of resources, expertise, and data, which enhances research capabilities. As the industry continues to evolve, such partnerships are likely to become more prevalent, facilitating the exchange of knowledge and driving advancements in AI applications within bioinformatics.

### Growing Focus on Preventive Healthcare

The shift towards preventive healthcare is significantly influencing the Artificial Intelligence in Bioinformatics Market. With an increasing emphasis on early disease detection and management, AI technologies are being leveraged to analyze patient data and identify risk factors. This proactive approach not only improves patient outcomes but also reduces healthcare costs. The market for preventive healthcare solutions is expanding, and AI's role in bioinformatics is becoming increasingly vital. By enabling more accurate risk assessments and personalized health strategies, AI is poised to play a crucial role in the future of healthcare.

### Rising Demand for Genomic Data Analysis

The Artificial Intelligence in Bioinformatics Market is experiencing a surge in demand for genomic data analysis. As the volume of genomic data generated continues to increase, the need for advanced analytical tools becomes paramount. AI technologies, particularly machine learning algorithms, are being employed to process and interpret complex genomic datasets. This trend is underscored by the fact that The Artificial Intelligence in Bioinformatics is projected to reach substantial figures, indicating a robust growth trajectory. The integration of AI in bioinformatics not only enhances the accuracy of genomic analyses but also accelerates the pace of research, thereby driving the market forward.

### Integration of AI with Big Data Technologies

The convergence of AI with big data technologies is reshaping the Artificial Intelligence in Bioinformatics Market. The ability to harness large volumes of biological data, coupled with AI's analytical capabilities, is enabling researchers to uncover insights that were previously unattainable. This integration facilitates real-time data processing and enhances predictive modeling, which is crucial for applications such as disease outbreak prediction and personalized treatment plans. As organizations increasingly adopt big data solutions, the synergy between AI and bioinformatics is likely to propel market growth, creating new opportunities for innovation.

## Future Outlook

The Artificial Intelligence in Bioinformatics Market is projected to grow at a 14.27% CAGR from 2025 to 2035, driven by advancements in data analytics, personalized medicine, and genomic research.

**New opportunities:**

- Development of AI-driven predictive analytics tools for drug discovery.
- Integration of machine learning algorithms in genomic sequencing.
- Creation of AI-based platforms for personalized treatment recommendations.

By 2035, the market is expected to be robust, reflecting substantial advancements and investment.

## Segment Insights

### By Application: Drug Discovery (Largest) vs. Biomarker Identification (Fastest-Growing)

In the Artificial Intelligence in Bioinformatics Market, the application segment showcases a diverse range of functionalities, with Drug Discovery capturing the largest market share. It plays a pivotal role in enhancing the efficiency of the drug development process, leading to quicker, more effective therapies. Following closely is Biomarker Identification, which is rapidly gaining traction due to its potential for early disease detection and personalized medicine, reflecting a considerable growth trend as healthcare providers increasingly prioritize precision in treatment.

Application: Drug Discovery (Dominant) vs. Biomarker Identification (Emerging)

Drug Discovery serves as the dominant force within the application segment of the Artificial Intelligence in Bioinformatics Market, primarily due to its crucial impact on pharmaceutical research and development. Leveraging AI technologies, it allows for the identification of potential drug candidates faster and more accurately than traditional methods. Conversely, Biomarker Identification is emerging as a significant player. Its ability to facilitate personalized medicine through the identification of unique biological markers drives its rapid adoption. This growing focus on improving patient outcomes through tailored therapies is likely to enhance its market standing in the coming years.

### By Deployment Mode: Cloud-Based (Largest) vs. On-Premise (Fastest-Growing)

In the Artificial Intelligence in Bioinformatics Market, the deployment mode shows a significant distribution between cloud-based and on-premise solutions. Cloud-based deployment currently holds the largest market share due to its scalability, flexibility, and reduced infrastructure costs. Organizations are increasingly adopting cloud-based solutions as they allow for easy access to data and computational resources, facilitating collaboration and enhancing efficiency across research teams.

Deployment Mode: Cloud-Based (Dominant) vs. On-Premise (Emerging)

Cloud-based deployment is dominating the Artificial Intelligence in Bioinformatics Market, characterized by its scalability and ease of access, which allows bioinformatics teams to harness vast amounts of data and computing power without significant investments in infrastructure. This model fosters collaboration among researchers and institutions globally. In contrast, on-premise solutions are emerging quickly, driven by concerns over data security, compliance with regulations, and the need for high-performance computing capabilities. While on-premise systems require more maintenance and investment, they cater to organizations that prioritize data control and security, making them an attractive alternative in specific sectors.

### By Data Offering: Software (Largest) vs. Services (Fastest-Growing)

The Data Offering segment in the Artificial Intelligence in Bioinformatics Market is primarily dominated by Software solutions, which command a significant market share due to their scalability and efficiency. As the demand for advanced data analysis and computational tools rises, Software remains the preferred choice among bioinformatics professionals. Conversely, Services, while smaller in share, are rapidly gaining traction as they cater to customized solutions and support, crucial for organizations navigating complex bioinformatics challenges.

Software (Dominant) vs. Services (Emerging)

Software solutions are at the forefront of the Artificial Intelligence in Bioinformatics Market, offering comprehensive tools for data analysis, genome sequencing, and visualization. Their dominance stems from their ability to integrate advanced algorithms and machine learning capabilities, providing users with powerful insights and automation. In contrast, the Services sector is emerging swiftly, focusing on consulting and implementation strategies that enhance the efficacy of software solutions. Organizations increasingly seek personalized services to address specific needs, which positions Services as a critical growth area that complements existing software offerings.

### By End User: Pharmaceutical & Biotechnology Companies (Largest) vs. Academic & Research Institutes (Fastest-Growing)

In the Artificial Intelligence in Bioinformatics Market, the distribution of market share among the end user segments reveals that Pharmaceutical & Biotechnology Companies hold the largest portion, driven by their extensive research and development activities and need for advanced technologies. Meanwhile, Academic & Research Institutes represent a significant and fast-growing segment, leveraging AI tools for groundbreaking studies and innovations in life sciences.

The growth trends indicate that the demand for AI in bioinformatics is accelerating in response to advancements in genomics and personalized medicine. Pharmaceutical & Biotechnology Companies are increasingly adopting AI technologies to enhance drug discovery processes. On the other hand, Academic & Research Institutes are experiencing a surge in adoption rate, with an emphasis on collaborative research and innovative solutions promoting rapid development in bioinformatics applications.

End Users: Pharmaceutical & Biotechnology Companies (Dominant) vs. Academic & Research Institutes (Emerging)

Pharmaceutical & Biotechnology Companies dominate the Artificial Intelligence in Bioinformatics Market, utilizing AI-driven analytics for drug discovery, clinical trial design, and patient stratification. Their extensive resources allow for significant investment in AI technologies, yielding competitive advantages in drug development timelines and effectiveness. In contrast, Academic & Research Institutes are identified as an emerging force in the sector, harnessing AI to enable innovative research into complex biological systems. They play a crucial role in fostering alliances with technology providers to access cutting-edge bioinformatics tools, which are essential for high-impact research and translating scientific discoveries into practical applications.

## Regional Market Share Analysis

### North America : Innovation and Investment Hub

North America is the largest market for Artificial Intelligence in Bioinformatics, holding approximately 45% of the global share. The region benefits from significant investments in healthcare technology, a robust research infrastructure, and a high demand for personalized medicine. Regulatory support from agencies like the FDA further catalyzes growth, promoting innovation and adoption of AI solutions in bioinformatics.

The United States is the primary driver of this market, with key players such as IBM, Illumina, and Thermo Fisher Scientific leading the charge. The competitive landscape is characterized by rapid technological advancements and collaborations between tech companies and healthcare providers. This synergy fosters an environment ripe for innovation, ensuring that North America remains at the forefront of AI applications in bioinformatics.

### Europe : Regulatory Framework and Growth

Europe is the second-largest market for Artificial Intelligence in Bioinformatics, accounting for around 30% of the global market share. The region's growth is driven by stringent regulations that promote data privacy and security, alongside increasing investments in healthcare innovation. The European Union's initiatives to enhance digital health technologies further support the adoption of AI in bioinformatics, creating a conducive environment for market expansion.

Leading countries in this region include Germany, the UK, and France, where companies like Siemens Healthineers and Roche are making significant strides. The competitive landscape is marked by a mix of established firms and innovative startups, all vying to leverage AI for improved healthcare outcomes. This dynamic fosters collaboration and knowledge sharing, positioning Europe as a key player in the AI bioinformatics space.

### Asia-Pacific : Rapid Growth and Adoption

Asia-Pacific is witnessing rapid growth in the Artificial Intelligence in Bioinformatics market, holding approximately 20% of the global share. The region's expansion is fueled by increasing healthcare expenditures, a growing population, and rising demand for advanced diagnostic tools. Governments are also investing in AI research and development, creating a favorable regulatory environment that encourages innovation and adoption of AI technologies in healthcare.

Countries like China, Japan, and India are at the forefront of this growth, with numerous startups and established companies entering the bioinformatics space. The competitive landscape is vibrant, characterized by collaborations between tech firms and healthcare institutions. This synergy is essential for driving advancements in AI applications, ensuring that Asia-Pacific remains a significant player in The Artificial Intelligence in Bioinformatics.

### Middle East and Africa : Emerging Market Potential

The Middle East and Africa region is gradually emerging in the Artificial Intelligence in Bioinformatics market, currently holding about 5% of the global share. The growth is driven by increasing investments in healthcare infrastructure and a rising awareness of the benefits of AI in medical research. Governments are beginning to recognize the potential of AI technologies, leading to supportive policies that encourage innovation in bioinformatics.

Countries like South Africa and the UAE are leading the charge, with a growing number of initiatives aimed at integrating AI into healthcare systems. The competitive landscape is still developing, with both local and international players exploring opportunities in this space. As the region continues to invest in technology and healthcare, the potential for growth in AI bioinformatics is significant.

## Competitive Benchmarking

Artificial intelligence in Bioinformatics market has been dominated by key players who are always striving to be ahead of their competitors through the creation of new products and solutions. The leading players in the Artificial intelligence bioinformatics market heavily invest in R&D so as to stay ahead of the current and adapt to the changing needs of customers. Strategic collaborations, partnerships, and acquisitions are among the characteristics that define the development landscape of Artificial Intelligence in Bioinformatics Market as firms seek to expand their portfolios, reach into new technologies, and explore new markets.IBM is one of the major players in the Artificial Intelligence in Bioinformatics Market. Watson for Genomics represents a comprehensive portfolio of AI-enabled bioinformatics tools developed by IBM. It helps researchers process enormous genomics data sets. IBM has a strong presence across healthcare and life sciences industries, thus leveraging its domain expertise to drive AI adoption in bioinformatics. Another key player within this industry is Illumina, which is an AI-based high-throughput sequencing provider with various supportive genomic research tools they developed.The main objective behind developing these AI-based approaches at Illumina includes identifying genetic variations, analyzing gene expression data, and coming up with personalized medications.Thermo Fisher Scientific, QIAGEN, and Agilent Technologies are also other significant participants of Artificial Intelligence in Bioinformatics Market besides IBM and Illumina. These firms provide a wide array of AI-driven bioinformatic solutions that include analytics tools for drug discovery or precision medicine. There is stiff competition among these companies, so they constantly innovate to avoid being outdone.

## Recent News & Developments

To sum up, the adoption of AI in life sciences and healthcare will drive AI bioinformatics market growth significantly in the next few years. Increased database availability is among the major factors that are increasing market expansion. Moreover, the rise in cases of chronic ailments and individualized medication are also some of the drivers of this industry.

Of note, there have been recent changes that have led to the Introduction of new bioinformatics platforms based on AI. For instance, in 2023, IBM and Recursion Pharmaceuticals joined forces to use artificial intelligence (AI) in searching for drugs that can cure various rare diseases.

Major companies such as Microsoft, Google, Amazon, Oracle, and IBM are among the notable players here. These firms have made considerable investments towards developing AI-driven innovative bioinformatics solutions through research and development activities.

## Report Scope

| MARKET SIZE 2024 | 8.765(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 10.02(USD Billion) |
| MARKET SIZE 2035 | 38.03(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.27% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | IBM (US), Illumina (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Siemens Healthineers (DE), Roche (CH), Agilent Technologies (US), Boehringer Ingelheim (DE), GSK (GB) |
| Segments Covered | Application, Offering, Deployment Mode, End User, Regional |
| Key Market Opportunities | Integration of advanced machine learning algorithms enhances genomic data analysis in the Artificial Intelligence in Bioinformatics Market. |
| Key Market Dynamics | Rising integration of artificial intelligence enhances data analysis capabilities, driving innovation in bioinformatics applications. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of Artificial Intelligence in Bioinformatics by 2035?**
A: The projected market valuation for Artificial Intelligence in Bioinformatics is expected to reach 38.03 USD Billion by 2035.

**Q: What was the market valuation of Artificial Intelligence in Bioinformatics in 2024?**
A: The overall market valuation for Artificial Intelligence in Bioinformatics was 8.765 USD Billion in 2024.

**Q: What is the expected CAGR for the Artificial Intelligence in Bioinformatics Market from 2025 to 2035?**
A: The expected CAGR for the Artificial Intelligence in Bioinformatics Market during the forecast period 2025 - 2035 is 14.27%.

**Q: Which companies are considered key players in the Artificial Intelligence in Bioinformatics Market?**
A: Key players in the market include IBM, Illumina, Thermo Fisher Scientific, Bio-Rad Laboratories, Siemens Healthineers, Roche, Agilent Technologies, Boehringer Ingelheim, and GSK.

**Q: What are the main applications of Artificial Intelligence in Bioinformatics and their market values?**
A: Main applications include Drug Discovery valued at 10.5 USD Billion, Biomarker Identification at 6.5 USD Billion, and Genomics Analysis at 8.0 USD Billion by 2035.

**Q: How does the deployment mode impact the market valuation of Artificial Intelligence in Bioinformatics?**
A: The Cloud-Based deployment mode is projected to reach 23.03 USD Billion, while On-Premise is expected to reach 15.0 USD Billion by 2035.

**Q: What are the data offerings in the Artificial Intelligence in Bioinformatics Market?**
A: Data offerings include Software projected at 15.5 USD Billion and Services at 22.53 USD Billion by 2035.

**Q: Who are the primary end users of Artificial Intelligence in Bioinformatics?**
A: Primary end users include Pharmaceutical & Biotechnology Companies, expected to reach 15.0 USD Billion, and Academic & Research Institutes at 8.0 USD Billion by 2035.

**Q: What is the significance of the growth in the Artificial Intelligence in Bioinformatics Market?**
A: The growth in the market indicates a rising demand for advanced analytical tools in bioinformatics, driven by innovations from key players.

**Q: How does the market for Artificial Intelligence in Bioinformatics compare across different segments?**
A: The market shows varied growth across segments, with Drug Discovery and Cloud-Based deployment leading in projected valuations by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-bioinformatics-market-22235*